Stoke Therapeutics, Inc. financial data

Symbol
STOK on Nasdaq
Industry
Pharmaceutical Preparations
Location
45 Wiggins Avenue, Bedford, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
ASOthera Pharmaceuticals, Inc. (to 11/24/2014)
Latest financial report
10-K - Q4 2024 - Mar 18, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 574 % -34.7%
Debt-to-equity 27.7 % -24.6%
Return On Equity -42.2 % +25.8%
Return On Assets -33 % +20.6%
Operating Margin -277 % +78.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54.1M shares +16.8%
Common Stock, Shares, Outstanding 54M shares +17.7%
Entity Public Float 528M USD +82.1%
Common Stock, Value, Issued 5K USD 0%
Weighted Average Number of Shares Outstanding, Basic 54M shares +22.8%
Weighted Average Number of Shares Outstanding, Diluted 54M shares +22.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 36.6M USD +316%
Research and Development Expense 89.1M USD +8.39%
General and Administrative Expense 48.8M USD +18.1%
Operating Income (Loss) -101M USD +11.7%
Nonoperating Income (Expense) 12.4M USD +23%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -89M USD +15%
Earnings Per Share, Basic -1.65 USD/shares +30.7%
Earnings Per Share, Diluted -1.65 USD/shares +30.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 128M USD -33.1%
Other Assets, Current 3.97M USD +54.8%
Assets, Current 233M USD +8.09%
Property, Plant and Equipment, Net 3.91M USD -32.9%
Operating Lease, Right-of-Use Asset 4.35M USD -34.3%
Assets 272M USD +18.9%
Accounts Payable, Current 2.5M USD +47.4%
Liabilities, Current 40.1M USD +30%
Operating Lease, Liability, Noncurrent 2.45M USD -48.6%
Other Liabilities, Noncurrent 2.48M USD -49.3%
Liabilities 42.5M USD -38.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -151K USD -529%
Retained Earnings (Accumulated Deficit) -491M USD -22.1%
Stockholders' Equity Attributable to Parent 229M USD +43.5%
Liabilities and Equity 272M USD +18.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.6M USD -15%
Net Cash Provided by (Used in) Financing Activities 1.72M USD -96.2%
Net Cash Provided by (Used in) Investing Activities 9.99M USD -81.2%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 54M shares +17.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.9M USD -117%
Deferred Tax Assets, Valuation Allowance 166M USD +24.2%
Deferred Tax Assets, Gross 166M USD +24.2%
Operating Lease, Liability 4.77M USD -30.2%
Depreciation 563K USD -5.7%
Payments to Acquire Property, Plant, and Equipment 12K USD -92.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -89.1M USD +13.9%
Lessee, Operating Lease, Liability, to be Paid 5.23M USD -33.3%
Property, Plant and Equipment, Gross 12.8M USD +2.11%
Operating Lease, Liability, Current 2.32M USD +12.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.56M USD -3.65%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.66M USD +2.03%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 451K USD -54.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.56M USD +1391%
Deferred Tax Assets, Operating Loss Carryforwards 70.1M USD +33.2%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 720M USD +28.2%
Share-based Payment Arrangement, Expense 27.5M USD +8.76%